



Are you satisfied with your current dermatomyositis treatment?

If you are still experiencing symptoms of dermatomyositis with your current treatment, you may be interested in learning about a clinical study sponsored by Priovent Therapeutics.

The **VALOR Study** is evaluating an investigational medicine called brepocitinib to see if it may improve symptoms of dermatomyositis in adults 18 to 75 years old.



How long is the study?

Your participation in the study may last up to 116 weeks, and you will have a visit to the study site approximately every 4 to 12 weeks.

Screening Period	Blinded Treatment Period	Open-label Extension Period	Follow-up Period
Up to 8 weeks	52 weeks (1 year)	52 weeks (1 year)	4 weeks

Once you complete the Blinded Treatment Period, you may have the option to continue in an Open-label Extension Period.



Why should I participate?

If you are eligible and decide to participate, you will:

- Receive study drug at no cost.
- Be closely monitored by the study doctor.
- Join others in helping to advance research for dermatomyositis.

Participation is voluntary, and if you decide to join, you can choose to stop at any time.

If you would like to learn more about the VALOR Study, contact:

To learn more about the VALOR Study, go to www.VALORStudy.com

